RecruitingNot applicableNCT06654596

Efficacy and Safety of Telitacicept in IgAN

Studying IgA Nephropathy

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ruijin Hospital
Intervention
Telitacicept 240mg(drug)
Enrollment
118 enrolled
Eligibility
18-70 years · All sexes
Timeline
2024 – 2026

Study locations (1)

Collaborators

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · RenJi Hospital · Sichuan Provincial People's Hospital · Renmin Hospital of Wuhan University · Shanghai 6th People's Hospital · Shanghai Longhua Hospital · Huashan Hospital · Shanghai Changzheng Hospital · Wannan Medical College Yijishan Hospital · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Songjiang Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06654596 on ClinicalTrials.gov

Other trials for IgA Nephropathy

Additional recruiting or active studies for the same condition.

See all trials for IgA Nephropathy →

← Back to all trials